Evidence map›Paper›PMID 39201062›Full record

ArticleJournal of clinical medicine2024

Real-World Comparison of Health-Related Quality of Life Associated with Use of Immune-Checkpoint Inhibitors in Oncology Patients.

Abdulrahman Alwhaibi, Miteb A Alenazi, Saad D Alnofaie, Abdullah M Aldekhail, Rakan J Alanazi, Sultan Alghadeer, Abdulrhman A Alghamdi, Saleh A Alanazi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Abdulrahman AlwhaibiDepartment of Clinical Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.ORCID 0000-0001-8519-3363
Miteb A AlenaziDepartment of Pediatrics, College of Medicine, King Saud University, Riyadh 11451, Saudi Arabia.
Saad D AlnofaieInformation Technology, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh 11426, Saudi Arabia.
Abdullah M AldekhailDepartment of Clinical Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
Rakan J AlanaziPharmacy Practice Department, College of Pharmacy, Alfaisal University, Riyadh 11533, Saudi Arabia.
Sultan AlghadeerDepartment of Clinical Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
Abdulrhman A AlghamdiPharmaceutical Services Department, Prince Sultan Military Medical City, Riyadh 11159, Saudi Arabia.
Saleh A AlanaziCollege of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh 14611, Saudi Arabia.

Funding

Researcher Supporting Project Number (RSPD-2024R572) King Saud University, Riyadh, Saudi Arabia RSPD-2024R572
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

atezolizumabdurvalumabhealthimmune checkpoint inhibitorsnivolumabpembrolizumabquality of life

Identifiers

PMID39201062
PMCPMC11355607

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.